Loading clinical trials...
Loading clinical trials...
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of TD-9855 in Patients With Fibromyalgia (FM)
Conditions
Interventions
TD-9855 Group 1
TD-9855 Group 2
+1 more
Locations
34
United States
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, United States
Dedicated Clinical Research
Goodyear, Arizona, United States
TriWest Research Associates, LLC
El Cajon, California, United States
Arroyo Medical Group, Inc.
Pismo Beach, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Coastal Connecticut Research, LLC
New London, Connecticut, United States
Start Date
November 1, 2012
Primary Completion Date
January 1, 2014
Completion Date
April 1, 2014
Last Updated
March 4, 2022
NCT07226648
NCT07358754
NCT05901259
NCT03759522
NCT07398417
NCT07230171
Lead Sponsor
Theravance Biopharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions